 |
Clinical Data
Results from a Phase 2b study of Stimuvax® in non-small cell lung cancer have been promising. In this study, 171 patients were randomized to receive either Stimuvax® plus best standard of care or best standard of care alone. Study endpoints were safety and survival with quality of life and immune response as secondary endpoints. Thirteen sites in Canada and four in the United Kingdom participated in the trial. The median survival for that subset of patients with Stage IIIB NSCLC (locoregional disease) was 30.6 months for patients treated with Stimuvax® plus best standard of care versus 13.3 months for the patients treated with best standard of care alone.
|
|
